Bayer Falls Short in Bid to Beat Eliquis in Afib, But Key Stroke Study Continues

Retrieved on: 2023-11-20 17:41:23

Tags for this article:

Aspirin

Bayer

IG Farben

Leverkusen

Direct factor Xa inhibitors

Transient ischemic attack

Bristol-Myers Squibb

Pfizer

The Bayer

Click the tags to see associated articles and topics

Bayer Falls Short in Bid to Beat Eliquis in Afib, But Key Stroke Study Continues. View article details on HISWAI: https://medcitynews.com/2023/11/bayer-falls-short-in-bid-to-beat-eliquis-in-afib-but-key-stroke-study-continues/

Excerpt

An independent data monitoring committee concluded Bayer's experimental drug for atrial fibrillation would not be more effective than Eliquis, ...

Article found on: medcitynews.com

View Original Article